August 26, 2009 (FinancialWire) — Biopharmaceutical firm GenVec, Inc. (NASDAQ: GNVC) (Current Market Cap: $76.71 Mil.) said it has received a small business grant, valued at around $2.5 million over three years, from an institute of the National Institutes of Health to support the development of GenVec’s vector production technology.

The company said it will use funds from the grant to support the development of novel cell lines capable of producing vaccine vectors based on different human serotype groups and encoding inhibitory antigens.

company executive Doug Brough said, “This important grant will support work to advance our cell line technology and enhance GenVec’s ability to discover and develop new adenovector-based vaccines and therapeutics.”

Gaithersburg, Maryland-based GenVec’s lead product, TNFerade, is currently in a clinical study in locally advanced pancreatic cancer.

The company also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus, and HSV-2.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.